The recent volumes surge in SPEX is an indication that there is enhanced technical strength in the stock. The 10 day average volumes (57K) are six times the 3 months (9.5K) average. This is mainly because of some big trading volume days in the last month. It has moved from $6.5 to $13.91 in one month thereby crossing the 50 and the 200DMA with volumes. It is good to remember that in the recent private placement of shares (November 2012) for $2.6M, Spherix issued 483K shares of common stock at $5.324 per share along with warrants to purchase an additional 483,657 at an exercise price of $6.53 per share. This is the point from which the recent upsurge has taken place. The $14 level is crucial as it is a retracement point for the 52W range. If this is crossed with volumes, then doors are open for $16 and then $20 and beyond. The volumes have to work in favor of the uptrend. The recent coverage in some reports points to fundamental potential of the company's drug development activity based on the size of the relevant market. The expected positive effect of divestiture of the consulting division to Chromadex is expected to reduce overheads and help the company to focus more on research and drug development and also to identify more & newer business opportunities. This will obviously reduce the strain on the cash flow and also work to reduce the dependence on external funding. The company is mainly funded through equity and 37% of the stocks are held by insiders. All these indications signal that, minor glitches apart, the uptrend may continue. More confidence will emerge after the $14 level is crossed. So that is a point to watch. The momentum is definitely there and the odds are in favor of continued uptrend. Next few days will be interesting.